SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await the July 29th FDA Advisory Committee review of deramiocel, with the community closely monitoring for details on label breadth and potential FDA concerns ahead of the August 22nd decision date. Sentiment is heavily focused on the drug's clinical data from the HOPE-3 trial and a recent physician-led letter to the FDA advocating for a dual-indication approval covering both skeletal muscle function and cardiomyopathy.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's securing of a significant National Science Foundation grant and its inclusion as a Leader in a major industry assessment. The community is actively debating the company's valuation and long-term potential, with many focusing on whether recent government-backed quantum initiatives will successfully translate into sustainable commercial growth.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after announcing a 53 million dollar private placement, which has triggered intense community speculation regarding potential institutional backing and a significant short squeeze. Traders are actively debating the stock's momentum versus the high risk of future dilution, as the company works to fund the development of its autoimmune pipeline.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion on YARTEMLEA in Europe, triggering significant volatility despite ongoing U.S. commercial efforts. The community is actively debating the impact of the EMA setback versus the potential for a successful appeal and upcoming domestic catalysts like J-code implementation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors respond to new executive orders designed to accelerate national quantum technology leadership and upgrade data security standards. The community is actively debating the stock's potential as a government-backed play, with many participants weighing the influence of federal catalysts against concerns regarding long-term cash burn and past volatility.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward pressure and market volatility following a major leadership transition and ongoing concerns regarding competitive threats in the multiple myeloma space. While the community remains divided, many investors are focused on the long-term potential of its CARVYKTI sales and a robust pipeline, leading to active debates about whether the current price represents a strategic buying opportunity or a signal to brace for further instability.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trading under significant volatility as investors weigh the potential impact of regulatory pipeline permit rejections against the stock's role in the long-term AI data center power buildout. The community remains deeply divided, with some traders actively shorting the stock amidst short-seller reports and negative sentiment, while others are aggressively buying the dip in anticipation of an upcoming earnings release and sustained institutional support for the company's fuel cell technology.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors weigh its potential as a key player in Western rare earth supply chains against volatility in the critical minerals sector and ongoing discussions regarding its Tanbreez project's development timeline. Community discourse is highly polarized, with intense debate centered on management transparency, the impact of recent dilution, and speculation surrounding upcoming tender opportunities for major rare earth deposits.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the following business segments: FEI-NY and FEI-Zyfer. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is seeing strong investor interest driven by its role in critical national security and space infrastructure, including the Golden Dome missile defense system and quantum sensing technology. The community is actively discussing its low float, growing order backlog, and potential for long-term growth as the company transitions into a key supplier for high-end aerospace and defense programs.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following a record-breaking $266 million contract award from the U.S. Space Force for multiple suborbital missions. While the community is actively discussing this major government validation and expansion into a new launch complex in Alaska, many investors remain focused on the broader volatility of the space sector and are expressing frustration over the stock's sensitivity to macroeconomic headwinds and peer performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
